C82.59
BillableDiffuse follicle center lymphoma, extranodal and solid organ sites
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C82.59 an HCC code?
Yes. C82.59 maps to Breast, Prostate, Colorectal and Other Cancers and Tumors under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C82.59
For C82.59 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C82.59 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C82.59 is the ICD-10-CM diagnosis code for diffuse follicle center lymphoma, extranodal and solid organ sites. This is a type of cancer that starts in the lymph system (specifically in follicle center cells) and has spread to organs outside the lymph nodes, such as the liver, lungs, or other solid organs. It is a slow-growing form of lymphoma that affects areas beyond the typical lymph node locations. C82.59 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C82.59 maps to Breast, Prostate, Colorectal and Other Cancers and Tumors (HCC 21) with a community, non-dual, aged base RAF weight of 0.545. Under the older CMS-HCC V24 model, C82.59 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Verify documentation specifies both the diffuse follicle center lymphoma type AND the extranodal/solid organ site involvement before assigning this code. Because C82.59 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C82.59 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Verify documentation specifies both the diffuse follicle center lymphoma type AND the extranodal/solid organ site involvement before assigning this code
- •Ensure the site of involvement is clearly documented (e.g., liver, lung, GI tract) as this specificity is required for accurate coding of extranodal disease
Clinical Significance
Diffuse follicle center lymphoma at extranodal and solid organ sites represents stage IV disease with involvement beyond the lymphatic system. Common extranodal sites include bone marrow, gastrointestinal tract, liver, lungs, and skin. Extranodal spread indicates more aggressive disease behavior and typically requires combination chemoimmunotherapy. The specific organs involved can significantly impact treatment approach, prognosis, and potential complications.
Documentation Requirements
- ✓Pathology confirming diffuse follicle center lymphoma at the extranodal site
- ✓Specific identification of which extranodal organs are involved
- ✓Biopsy confirmation of extranodal involvement (not just imaging)
- ✓Staging documentation with stage IV designation
- ✓Assessment of organ function impacted by the lymphoma (liver function, renal function, etc.)
- ✓Documentation of any complications from extranodal disease